Raj C Dedhia, Donald L Bliwise, Arshed A Quyyumi, Erica R Thaler, Maurits S Boon, Colin T Huntley, Everett G Seay, Akshay Tangutur, Patrick J Strollo, Nil Gurel, Brendan T Keenan
IMPORTANCE: Sham-controlled trials are needed to characterize the effect of hypoglossal nerve stimulation (HGNS) therapy on cardiovascular end points in patients with moderate-severe obstructive sleep apnea (OSA). OBJECTIVE: To determine the effect of therapeutic levels of HGNS, compared to sham levels, on blood pressure, sympathetic activity, and vascular function. DESIGN, SETTING, AND PARTICIPANTS: This double-blind, sham-controlled, randomized crossover therapy trial was conducted from 2018 to 2022 at 3 separate academic medical centers...
January 1, 2024: JAMA Otolaryngology—Head & Neck Surgery